Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(3.31)
# 1,046
Out of 5,044 analysts
80
Total ratings
44.05%
Success rate
5.03%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RANI Rani Therapeutics Holdings | Assumes: Buy | $11 | $1.78 | +517.98% | 3 | Oct 21, 2025 | |
| OMER Omeros | Maintains: Buy | $9 → $20 | $7.71 | +159.40% | 3 | Oct 15, 2025 | |
| MNKD MannKind | Reiterates: Buy | $11 | $5.42 | +102.95% | 6 | Oct 13, 2025 | |
| GNFT Genfit | Maintains: Buy | $9 → $7 | $4.17 | +68.03% | 2 | Sep 24, 2025 | |
| RNTX Rein Therapeutics | Initiates: Buy | $10 | $1.35 | +640.74% | 1 | Sep 22, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $93 → $121 | $92.86 | +30.30% | 6 | Sep 17, 2025 | |
| VALN Valneva SE | Reiterates: Buy | $18 | $9.32 | +93.13% | 2 | Aug 25, 2025 | |
| DERM Journey Medical | Initiates: Buy | $13 | $8.02 | +62.09% | 2 | Aug 25, 2025 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $12 | $4.68 | +156.41% | 2 | Aug 21, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Reiterates: Buy | $12 | $5.53 | +117.00% | 3 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $3.61 | +260.11% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.60 | +337.50% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $10 | $9.31 | +7.41% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $44 | $34.82 | +26.38% | 6 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $11.05 | +53.85% | 3 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $29 | $8.60 | +237.21% | 1 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $24.78 | +12.99% | 1 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $10.50 | +90.48% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $11.08 | +134.66% | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.18 | +408.47% | 2 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $5 | $1.91 | +161.78% | 2 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.22 | +637.70% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $10.50 | +100.00% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.14 | +338.60% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.36 | +2,092.38% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $9.69 | +65.12% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $18.99 | +2,296.00% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $30.51 | +93.38% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $139.33 | +29.19% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $220 | $3.80 | +5,689.47% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $29.72 | +7.67% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.57 | +1,401,173.89% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $17.39 | +187.52% | 1 | Jul 12, 2018 |
Rani Therapeutics Holdings
Oct 21, 2025
Assumes: Buy
Price Target: $11
Current: $1.78
Upside: +517.98%
Omeros
Oct 15, 2025
Maintains: Buy
Price Target: $9 → $20
Current: $7.71
Upside: +159.40%
MannKind
Oct 13, 2025
Reiterates: Buy
Price Target: $11
Current: $5.42
Upside: +102.95%
Genfit
Sep 24, 2025
Maintains: Buy
Price Target: $9 → $7
Current: $4.17
Upside: +68.03%
Rein Therapeutics
Sep 22, 2025
Initiates: Buy
Price Target: $10
Current: $1.35
Upside: +640.74%
ANI Pharmaceuticals
Sep 17, 2025
Maintains: Buy
Price Target: $93 → $121
Current: $92.86
Upside: +30.30%
Valneva SE
Aug 25, 2025
Reiterates: Buy
Price Target: $18
Current: $9.32
Upside: +93.13%
Journey Medical
Aug 25, 2025
Initiates: Buy
Price Target: $13
Current: $8.02
Upside: +62.09%
Achieve Life Sciences
Aug 21, 2025
Initiates: Buy
Price Target: $12
Current: $4.68
Upside: +156.41%
Eupraxia Pharmaceuticals
Aug 20, 2025
Reiterates: Buy
Price Target: $12
Current: $5.53
Upside: +117.00%
Aug 13, 2025
Reiterates: Buy
Price Target: $13
Current: $3.61
Upside: +260.11%
Aug 13, 2025
Reiterates: Buy
Price Target: $7
Current: $1.60
Upside: +337.50%
Aug 12, 2025
Assumes: Buy
Price Target: $10
Current: $9.31
Upside: +7.41%
Aug 11, 2025
Assumes: Buy
Price Target: $44
Current: $34.82
Upside: +26.38%
Aug 8, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $11.05
Upside: +53.85%
Aug 7, 2025
Assumes: Buy
Price Target: $29
Current: $8.60
Upside: +237.21%
Aug 6, 2025
Initiates: Buy
Price Target: $28
Current: $24.78
Upside: +12.99%
Jul 28, 2025
Assumes: Buy
Price Target: $20
Current: $10.50
Upside: +90.48%
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $11.08
Upside: +134.66%
Jun 9, 2025
Initiates: Buy
Price Target: $6
Current: $1.18
Upside: +408.47%
Jun 5, 2025
Assumes: Buy
Price Target: $5
Current: $1.91
Upside: +161.78%
Jun 2, 2025
Initiates: Buy
Price Target: $9
Current: $1.22
Upside: +637.70%
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $10.50
Upside: +100.00%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $1.14
Upside: +338.60%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.36
Upside: +2,092.38%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $9.69
Upside: +65.12%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $18.99
Upside: +2,296.00%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $30.51
Upside: +93.38%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $139.33
Upside: +29.19%
Dec 5, 2022
Maintains: Overweight
Price Target: $300 → $220
Current: $3.80
Upside: +5,689.47%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $29.72
Upside: +7.67%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.57
Upside: +1,401,173.89%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $17.39
Upside: +187.52%